Physicians Treating Few Patients With Buprenorphine

Share this content:
Physicians Treating Few Patients With Buprenorphine
Physicians Treating Few Patients With Buprenorphine

WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- For buprenorphine prescribers, the monthly patient census is 13 patients, according to a research letter published in the Sept. 20 issue of the Journal of the American Medical Association.

Bradley D. Stein, M.D., Ph.D., from the RAND Corporation in Pittsburgh, and colleagues analyzed data from the Symphony Health Solutions' Integrated Dataverse for seven states with the most buprenorphine-waivered physicians, who are restricted in the number of patients with opioid disorders that they can treat concurrently. The number of patient episodes (starting with the first observed buprenorphine claim) for each provider were summed to calculate monthly patient census.

The researchers identified 3,234 buprenorphine prescribers with 245,016 patients receiving a new prescription of buprenorphine. The monthly patient census for prescribers was 13 patients, with median episode duration of 53 days. Overall, 22, 49, 20, and 9 percent of prescribers had monthly censuses of one to three, four to 30, 31 to 75, and more than 75 patients, respectively. In years subsequent to 2010, there was an increase in patient census. The lowest census was seen in California and the highest in Massachusetts and Pennsylvania.

"Strategies to help current prescribers treat more patients safely and effectively could complement policy initiatives designed to increase access to treatment by increasing patient limits and number of waivered prescribers," the authors write.

One author disclosed financial ties to the pharmaceutical industry; two authors disclosed ties to the publishing industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »